998 HIGH-RISK PROSTATE CANCER PRESENTING WITH BIOPSY GLEASON SCORE 8, 9 OR 10: DOWNGRADING AND CANCER-SPECIFIC SURVIVAL

Steven Joniau, Paolo Gontero(Fondazione Ricerca Molinette), Henk G. van der Poel(Amsterdam University Medical Centers), Bertrand Tombal(Cliniques Universitaires Saint-Luc), G. Marchioro(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), P. Bastian, Alberto Briganti(University College London Hospitals NHS Foundation Trust), Bruno Frea(Ospedale Maggiore), Martin Spahn(Universitätsklinikum Würzburg), Francesco Montorsi(Vita-Salute San Raffaele University), Chao‐Yu Hsu(National Chung Hsing University)
The Journal of Urology
April 1, 2012
10.1016/j.juro.2012.02.1099
Cited by 0

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
|The Lancet|2012|864
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
|European Urology|2015|639
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
|New England Journal of Medicine|2020|442